CJ Bioscience, Inc. (KOSDAQ: 311690)
South Korea
· Delayed Price · Currency is KRW 11,490
-220 (-1.88%)
Sep 11, 2024, 9:00 AM KST
CJ Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 4,899 | 5,575 | 4,075 | 4,363 | 5,312 | 4,783 | Upgrade
|
| Other Revenue | - | -0 | - | - | - | - | Upgrade
|
| Revenue | 4,899 | 5,575 | 4,075 | 4,363 | 5,312 | 4,783 | Upgrade
|
| Revenue Growth (YoY) | -4.74% | 36.82% | -6.61% | -17.86% | 11.05% | 21.90% | Upgrade
|
| Cost of Revenue | 3,687 | 3,802 | 2,763 | 2,721 | 3,072 | 2,120 | Upgrade
|
| Gross Profit | 1,212 | 1,773 | 1,311 | 1,642 | 2,240 | 2,663 | Upgrade
|
| Selling, General & Admin | 8,349 | 9,371 | 12,970 | 5,934 | 5,375 | 3,465 | Upgrade
|
| Research & Development | 22,071 | 22,823 | 19,186 | 4,852 | 4,984 | 3,399 | Upgrade
|
| Other Operating Expenses | 233.17 | 203.41 | 111.59 | 77.13 | 17.09 | 9.58 | Upgrade
|
| Operating Expenses | 32,084 | 33,829 | 34,545 | 11,750 | 10,753 | 7,182 | Upgrade
|
| Operating Income | -30,872 | -32,057 | -33,233 | -10,108 | -8,513 | -4,519 | Upgrade
|
| Interest Expense | -767.76 | -922.05 | -2,763 | -4,968 | -1,622 | -45.33 | Upgrade
|
| Interest & Investment Income | 1,778 | 1,367 | 1,331 | 410.15 | 337.88 | 205.7 | Upgrade
|
| Earnings From Equity Investments | 75.66 | 75.66 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -32.98 | -39.39 | 12.64 | 2.91 | 0.69 | 6.52 | Upgrade
|
| Other Non Operating Income (Expenses) | 8.96 | 19.86 | 129.82 | -2,485 | 1,124 | 6.26 | Upgrade
|
| EBT Excluding Unusual Items | -29,809 | -31,555 | -34,523 | -17,148 | -8,673 | -4,346 | Upgrade
|
| Gain (Loss) on Sale of Assets | 8,643 | 8,642 | -390.7 | 10.43 | -89.96 | -0.01 | Upgrade
|
| Asset Writedown | - | - | - | -170.67 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -1,964 | - | - | Upgrade
|
| Pretax Income | -21,166 | -22,913 | -34,913 | -19,272 | -8,763 | -4,346 | Upgrade
|
| Net Income | -21,166 | -22,913 | -34,913 | -19,272 | -8,763 | -4,346 | Upgrade
|
| Net Income to Common | -21,166 | -22,913 | -34,913 | -19,272 | -8,763 | -4,346 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 7 | 6 | 4 | 4 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 7 | 6 | 4 | 4 | 3 | Upgrade
|
| Shares Change (YoY) | 47.97% | 20.52% | 38.23% | 10.14% | 16.93% | 2.78% | Upgrade
|
| EPS (Basic) | -2433.24 | -3234.63 | -5940.02 | -4532.31 | -2269.60 | -1316.15 | Upgrade
|
| EPS (Diluted) | -2433.54 | -3235.00 | -5940.02 | -4533.00 | -2270.00 | -1317.00 | Upgrade
|
| Free Cash Flow | -26,219 | -29,823 | -25,108 | -9,390 | -19,997 | -2,933 | Upgrade
|
| Free Cash Flow Per Share | -3014.06 | -4210.07 | -4271.74 | -2208.24 | -5179.37 | -888.40 | Upgrade
|
| Gross Margin | 24.75% | 31.80% | 32.19% | 37.62% | 42.17% | 55.68% | Upgrade
|
| Operating Margin | -630.16% | -575.00% | -815.61% | -231.68% | -160.28% | -94.47% | Upgrade
|
| Profit Margin | -432.06% | -410.99% | -856.84% | -441.72% | -164.97% | -90.85% | Upgrade
|
| Free Cash Flow Margin | -535.19% | -534.93% | -616.19% | -215.22% | -376.48% | -61.33% | Upgrade
|
| EBITDA | -26,118 | -26,911 | -29,333 | -8,546 | -7,462 | -3,788 | Upgrade
|
| EBITDA Margin | - | - | - | -195.88% | -140.49% | -79.19% | Upgrade
|
| D&A For EBITDA | 4,754 | 5,146 | 3,900 | 1,562 | 1,051 | 730.98 | Upgrade
|
| EBIT | -30,872 | -32,057 | -33,233 | -10,108 | -8,513 | -4,519 | Upgrade
|
| EBIT Margin | - | - | - | -231.68% | -160.28% | -94.47% | Upgrade
|
| Advertising Expenses | - | 160.85 | 131.39 | 58.02 | 979.43 | 221.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.